ホーム › 膵臓がん › マサチューセッツ州 › Boston
Boston、MAにおける膵臓がんの臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、膵臓がんに関する43件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Boston
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
被験者募集中第3相
- Dana Farber Cancer Institute, Boston
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute (DFCI), Boston
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
被験者募集中第3相
- Investigative Site US022, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
被験者募集中観察研究
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
被験者募集中第2相
- Local Institution - 0124, Boston
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
被験者募集中観察研究
- Boston Children's Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pancreatic Cancer Early Detection Consortium
被験者募集中観察研究健康なボランティア歓迎
- Massachusetts General Hospital, Boston
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
被験者募集中第1相
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
被験者募集中第1相
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Boston
- Research Site, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
被験者募集中早期第1相健康なボランティア歓迎
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
被験者募集中
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
A Study of MGC028 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Mass General Brigham, Boston
- Dana Farber/Harvard Cancer Center, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
被験者募集中第2相
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
被験者募集中第2相
- Massachusetts General Hospital, Boston
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
被験者募集中
- Dana Farber Cancer Institute, Boston
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
被験者募集中第2相
- Ohio State University-Telemedicine, Boston
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
被験者募集中第3相
- Beth Israel Deaconess Medical Center, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
被験者募集中
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
The Cancer of the Pancreas Screening-5 CAPS5)Study
被験者募集中第3相
- Dana Farber Cancer Center, Harvard University, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
被験者募集中観察研究
- Beth Israel Deaconess Medical Center, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
被験者募集中第1相
- Dana Farber/Partners Cancer Care Inc, Boston
他の都市における膵臓がんの試験
- Houston, TX61件の研究
- New York City, NY60件の研究
- Nashville, TN39件の研究
- Los Angeles, CA35件の研究
- St. Louis, MO33件の研究
- Arlington, VA33件の研究
- Baltimore, MD31件の研究
- San Antonio, TX31件の研究
- Philadelphia, PA26件の研究
- Tampa, FL26件の研究
- Durham, NC24件の研究
- San Diego, CA24件の研究
Bostonにおける他の研究
- 乳がん112件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。